featured
-
August 2026: This month in Huntington’s disease research
August was another busy month for HD research! Learnings from past trials, new approaches to huntingtin lowering, the start of INSIGHTT and PRECISE-HD, three packed days at HD2026, and the HDBuzz Prize: we’ve got you covered.
-
First participant dosed in the PRECISE-HD trial of pridopidine
The first participant has now been dosed in the Phase 3 PRECISE-HD trial of pridopidine for HD. The study will test whether the drug can slow disease progression in people most likely to benefit
-
Taking A Short Cut: New Routes to Huntingtin-Lowering Therapies
⏱️5 min read | New research points to HTT1a, a toxic shortened form of huntingtin, as a key driver of disease and a promising therapeutic target in HD.
-
A shot in the arm for HTT lowering: INSIGHTT trial begins testing SRP-1005
A new Phase 1 study is testing SRP-1005, a huntingtin-lowering therapy given by injection under the skin. It’s early days, but this approach could add an important new arrow to the HD drug development quiver.
-
The 2026 HDBuzz Prize for Young Science Writers Is Open!
⏱️ 5 min read | Announcing the 2026 HDBuzz Prize for Young Science Writers – sponsored by the Hereditary Disease Foundation!
-
HD2026 Milton Wexler Biennial Symposium Day 3
Day 3 of #HD2026 put HTT under the microscope. Researchers shared new insights into HTT1a, next-generation HTT-lowering approaches, somatic expansion, brain circuitry, and why boosting healthy HTT might help. Read our roundup here.
-
HD2026 Milton Wexler Biennial Symposium Day 2
⏱️ 23 min read | Day 2 of #HD2026 brought us updates on the mechanics of somatic instability, new ways to track HD in people, AI tools to help drive research forward, and developments in our understanding of the HTT protein. Catch up right here.
-
HD2026 Milton Wexler Biennial Symposium Day 1
⏱️ 28 min read | Day 1 of HD2026 is a wrap! From what human brains can teach us about HD, to HTT1a, somatic CAG expansion and the normal biology of HTT, today’s talks spanned the spectrum from fundamental biology to potential treatments.
-
Prilenia shares HD trial data with CHDI to help future research
Clinical trial data can drive discovery long after a study ends. Prilenia donated placebo-arm data from 2 HD clinical trials to CHDI, a valuable resource for researchers to better understand placebo effects, HD progression and future trial design.
-
Looking back and moving forward: Questions and lessons 4 weeks out from Roche’s disappointing news
⏱️10min read | Roche’s decision to stop development of 2 HTT-lowering programmes is disappointing, but the story doesn’t end there. Years of research answered some key questions, raised many new ones, and will inform the next generation of HD trials.